

Beyond the Scale: Obesity as a Structural Driver of Refractory Hypertension

Eduardo Tibirica¹

Instituto Nacional de Cardiologia,¹ Rio de Janeiro, RJ – Brazil

Short Editorial related to the article: Impact of Obesity on Patients with Resistant and Refractory Arterial Hypertension: A Cross-Sectional Study

Arterial hypertension remains a global challenge, yet its extreme phenotypes—Resistant Hypertension (RAH) and Refractory (RefH) Hypertension—represent the forefront of cardiovascular risk. While RAH involves uncontrolled blood pressure (BP) despite three drug classes, RefH is its most severe manifestation, defined by failure with five or more drugs.¹ In Brazil, RAH is highly prevalent; the ELSA-Brasil study reported an 11% prevalence among treated patients, with higher risks for older, Black, and obese individuals.²

Expanding this landscape, Costa et al.³ provide a timely analysis of a high-complexity cohort. Their findings reveal a striking correlation between body mass index and pharmacological burden ($r = 0.45$; $p < 0.01$). This “dose-response” relationship suggests that in obese individuals, the “ceiling effect” of conventional therapy is reached sooner, necessitating an escalation of polypharmacy. Furthermore, by focusing on a cohort predominantly composed of Afro-descendant women over 60 years of age, the authors address a critical gap regarding vulnerable groups often underrepresented in clinical research.

The link between adiposity and therapeutic failure involves a complex interplay of neuro-hormonal and structural mechanisms. Visceral fat increases intra-abdominal pressure and causes physical renal compression, leading to the chronic activation of the renin-angiotensin-aldosterone system.⁴ Simultaneously, hyperleptinemia drives sympathetic overactivity,⁵ further sustaining high BP levels.

However, from a microcirculatory perspective, the impact of obesity is even more profound and insidious.

Obesity-induced chronic low-grade inflammation and lipotoxicity foster systemic oxidative stress,⁶ which significantly impairs nitric oxide bioavailability and triggers microvascular alterations, including functional capillary rarefaction and inward arteriolar remodeling.^{7–9} This endothelial dysfunction and subsequent microvascular stiffness drastically reduce the vascular bed’s responsiveness to both endogenous and pharmacological vasodilators.¹⁰ Consequently, a “structural barrier” is established, effectively explaining the intractable nature of BP and the poor response to heavy polypharmacy observed in the refractory group studied by Costa et al.³

Moreover, the evidence provided by Costa et al.³ suggest that traditional polypharmacy often reaches a “ceiling effect” in obese refractory patients. In this scenario, addressing adiposity becomes the primary antihypertensive strategy rather than a secondary goal. Emerging metabolic interventions, such as GLP-1 receptor agonists and bariatric surgery—the latter having demonstrated remarkable efficacy in achieving BP control and medication reduction in resistant hypertension, as shown in the landmark GATEWAY trial^{11,12}, offer promising pathways by directly targeting the underlying neuro-hormonal triggers of resistance.

Ultimately, this study reinforces that in the battle against severe hypertension, the weighing scale is as critical as the sphygmomanometer. Achieving BP targets in these vulnerable and underrepresented populations requires a paradigm shift, moving from purely pharmacological escalation toward comprehensive metabolic restoration.

References

- Cardoso CRL, Salles GF. Refractory Hypertension and Risks of Adverse Cardiovascular Events and Mortality in Patients with Resistant Hypertension: A Prospective Cohort Study. *J Am Heart Assoc.* 2020;9(17):e017634. doi: 10.1161/JAHA.120.017634.
- Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant Hypertension: Risk Factors, Subclinical Atherosclerosis, and Comorbidities among Adults—the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). *J Clin Hypertens.* 2015;17(1):74–80. doi: 10.1111/jch.12433.

Keywords

Hypertension; Arterial Pressure; Obesity

Mailing Address: Eduardo Tibirica •

Instituto Nacional de Cardiologia - Rua das Laranjeiras, 374. Postal code 22240-006, Rio de Janeiro, RJ – Brazil

E-mail: etibi@uol.com.br

Manuscript received February 25, 2026, revised manuscript March 04, 2026, accepted March 04, 2026

DOI: <https://doi.org/10.36660/abc.20260139i>

3. Costa BVPL, Bulhões F, Macedo C, Improtá-Caria AC, Aras Júnior R. Impact of Obesity on Patients with Resistant and Refractory Arterial Hypertension: A Cross-Sectional Study. *Arq Bras Cardiol.* 2026; 123(2):e20250627. doi: <https://doi.org/10.36660/abc.20250627i>.
4. Hall ME, Omoto ACM, Hall JE. Obesity, Fatty Kidney, and Hypertension: Potential Role of Aldosterone. *Hypertension.* 2025;82(11):1822-5. doi: 10.1161/HYPERTENSIONAHA.125.25627.
5. Lambert GW, Patel M, Lambert EA. The Influence of the Sympathetic Nervous System on Cardiometabolic Health in Response to Weight Gain or Weight Loss. *Metabolites.* 2025;15(5):286. doi: 10.3390/metabo15050286.
6. Cavaliere G, Cimmino F, Trinchese G, Catapano A, Petrella L, D'Angelo M, et al. From Obesity-Induced Low-Grade Inflammation to Lipotoxicity and Mitochondrial Dysfunction: Altered Multi-Crosstalk between Adipose Tissue and Metabolically Active Organs. *Antioxidants.* 2023;12(6):1172. doi: 10.3390/antiox12061172.
7. Boillot A, Zoungas S, Mitchell P, Klein R, Klein B, Ikram MK, et al. Obesity and the Microvasculature: A Systematic Review and Meta-Analysis. *PLoS One.* 2013;8(2):e52708. doi: 10.1371/journal.pone.0052708.
8. Lorenzo A, Estato V, Castro-Faria-Neto HC, Tibirica E. Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity. *J Inflamm Res.* 2021;14:2267-76. doi: 10.2147/JIR.S282710.
9. Virdis A, Masi S, Colucci R, Chiriaco M, Uliana M, Puxeddu I, et al. Microvascular Endothelial Dysfunction in Patients with Obesity. *Curr Hypertens Rep.* 2019;21(4):32. doi: 10.1007/s11906-019-0930-2.
10. Tibirica E, Lorenzo AL, Duque MD, Verri VV, Crahim VC. Systemic Functional and Structural Microvascular Alterations in Patients with Resistant Arterial Hypertension versus Non Resistant Hypertension. *Eur Heart J.* 2025;46(Suppl 1):ehaf784.3322. doi: 10.1093/eurheartj/ehaf784.3322.
11. Schiavon CA, Ikeoka DT, Sousa MC, Silva CR, Bersch-Ferreira AC, Oliveira JD, et al. Effects of Gastric Bypass Surgery in Patients with Hypertension: Rationale and Design for a Randomised Controlled Trial (GATEWAY study). *BMJ Open.* 2014;4(9):e005702. doi: 10.1136/bmjopen-2014-005702.
12. Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, et al. Effects of Bariatric Surgery in Obese Patients with Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). *Circulation.* 2018;137(11):1132-42. doi: 10.1161/CIRCULATIONAHA.117.032130.



This is an open-access article distributed under the terms of the Creative Commons Attribution License